Cartilage Oligomeric Matrix Protein As A Serological Biomarker for the Assessment of Liver Fibrosis Before and After Treatment of HCV Infection

Document Type : Original Article


1 Chemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt

2 Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt

3 Biochemistry department, Faculty of Science, Minia University

4 Biotechnology Research Center, New Dameitta 34517, Egypt

5 Biochemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt


The goal of this study was to determine cartilage oligomeric matrix protein (COMP) levels as a biochemical marker in various phases of hepatic fibrosis and to estimate its effectiveness for hepatic fibrosis monitoring. Eighty-eight patients with various stages of hepatic fibrosis were enrolled in this trial, all of whom had a sustained virological response after using direct-acting antivirals. Patients were followed-up after one year of treatment. FibroScan and COMP were determined before and after one year from the end of treatment. Liver enzymes such as alanine transaminase, aspartate transaminase, and alkaline phosphatase were measured in addition to albumin, total bilirubin, creatinine, and glucose. COMP levels increased with the progression of liver fibrosis, according to our findings. COMP enabled the correct identification of F2-F4, F3-F4 and F4 with areas under the curve of 0.765, 0.788 and 0.790, respectively. Our findings showed that 68.4%, 87.1%, and 98.6% of F4, F3-F4, and F4, respectively, were positive for COMP. Notably, the vast majority of individuals who tested positive for COMP were appropriately classified. In conclusion, this work provides a promising marker that might be used as a potential serologic biomarker for liver fibrosis staging and may facilitate definitive therapy as well as a complementary diagnostic tool in monitoring cirrhotic patients for detection of early HCC.


Main Subjects